Table 2 Comparison of neoadjuvant radiation and adjuvant radiation populations
From: Radiation therapy for retroperitoneal sarcoma: practice patterns in North America
Adjuvant Radiation N = 1091 (%)* | Neoadj uvant Radiation N = 730 (%)* | p value | |
|---|---|---|---|
Patient characteristics | |||
Age (Mean ± SD) | 60.91 (12.59) | 60.65 (12.57) | 0.751 |
Sex | < 0.001 | ||
Male | 473 (43.4) | 381 (52.2) | |
Female | 618 (56.7) | 349 (47.8) | |
Race | 0.174 | ||
Caucasian | 899 (82.4) | 621 (85.1) | |
African American | 136 (12.5) | 67 (9.2) | |
Asian | 37 (3.4) | 23 (3.2) | |
Other | 10 (0.9) | 11 (15) | |
Unknown | 9 (0.8) | 8 (1.1) | |
Ethnicity | 0.002 | ||
No Hispanic | 952 (87.3) | 675 (92.5) | |
Hispanic | 78 (7.2) | 33 (4.5) | |
Unknown | 61 (5.6) | 22 (3.0) | |
Great Circle Distance (Median, IQR) | 11.7 (4.9, 28.2) | 28.4 (9.8, 83.6) | < 0.001 |
Primary Payor | 0.672 | ||
Medicaid, Medicare, Other Government Insurance | 520 (47.7) | 333 (45.6) | |
Private Insurance | 530 (48.6) | 364 (49.9) | |
No Insurance | 30 (2.8) | 22 (3.0) | |
Unknown | 11 (10) | 11 (15) | |
Facility Location | < 0.001 | ||
New England/East Coast | 403 (36.9) | 364 (49.9) | |
Mid-West | 301 (27.6) | 173 (23.7) | |
South | 139 (12.7) | 46 (6.3) | |
West Coast | 192 (17.6) | 107 (147) | |
Unknown | 56 (5.1) | 40 (5.5) | |
Facility Type | < 0.001 | ||
Academic/Research Pro gram | 452 (41.4) | 504 (69.0) | |
Community Cancer Program | 76 (6.9) | 14 (1.9) | |
Comprehensive Community Cancer Program | 373 (34.2) | 106 (14.5) | |
Integrated Network Cancer Program | 134 (12.3) | 66 (9.0) | |
Unknown | 56 (5.1) | 40 (5.5) | |
Charlson-Deyo Score | 0.859 | ||
0 | 849 (77.8) | 574 (78.6) | |
1 | 190 (17.4) | 120 (164) | |
2 | 34 (3.1) | 21 (2.9) | |
≥3 | 18 (1.7) | 15 (2.1) | |
Year of diagnosis | < 0.001 | ||
2004 | 82 (7.5) | 21 (2.9) | |
2005 | 76 (6.9) | 14 (1.9) | |
2006 | 79 (7.2) | 33 (4.5) | |
2007 | 99 (9.1) | 28 (3.8) | |
2008 | 76 (6.9) | 33 (4.5) | |
2009 | 88 (8.1) | 41 (5.6) | |
2010 | 90 (8.3) | 51 (6.9) | |
2011 | 91 (8.3) | 59 (8.1) | |
2012 | 91 (8.3) | 52 (7.1) | |
2013 | 82 (7.5) | 66 (9.0) | |
2014 | 83 (7.6) | 66 (9.0) | |
2015 | 56 (5.1) | 68 (9.3) | |
2016 | 48 (4.4) | 87 (119) | |
2017 | 50 (4.6) | 111 (15.2) | |
Annual hospital volume | < 0.001 | ||
Average < 5 cases per year | 1008 (92.4) | 498 (68.2) | |
Average 5–10 cases per year | 74 (6.8) | 113 (15.5) | |
Average > 10 cases/year | 9 (0.8) | 119 (16.3) | |
Tumor Factors | |||
Tumor differentiation | 0.008 | ||
Well differentiated | 199 (18.2) | 166 (22.7) | |
Moderately differentiated | 173 (15.9) | 92 (12.6) | |
Poorly differentiated | 350 (32.1) | 195 (26.7) | |
Undifferentiated | 187 (17.1) | 140 (19.2) | |
Unknown | 182 (16.7) | 137 (18.8) | |
Histology | 0.056 | ||
Leiomyosarcoma | 398 (36.5) | 227 (31.1) | |
Liposarcoma | 534 (48.9) | 392 (53.7) | |
Other | 159 (14.6) | 111 (152) | |
Tumor size | < 0.001 | ||
< 10 cm | 374 (34.3) | 133 (18.2) | |
> 10 cm | 600 (54.9) | 394 (53.9) | |
Unknown | 117 (107) | 203 (27.8) | |
Tumor Grade | < 0.001 | ||
Grade 1 | 109 (9.9) | 118 (162) | |
Grade 2 | 127 (11.6) | 100 (137) | |
Grade 3 | 314 (28.8) | 268 (36.7) | |
Unknown | 541 (49.6) | 244 (33.4) | |